Innoray

Founded in 2022 and based in Shanghai, China, Innoray Healthcare Technology (Shanghai) Co. , Ltd. , dba Innoray, specializes in manufacturing dual-energy bone densitometers for the Chinese healthcare sector. In April 2026, Innoray raised a venture funding from GTJA Innovation Investment, NimoBay Investment and Wego Prefills.

Innoray specializes in advanced dual-energy bone densitometers, including the INNO-E and INNO-S models, designed to support osteoporosis screening, diagnosis, and treatment in China. Their products and supporting software, like Zhi Duo Xing for trabecular bone scoring, are widely used by hospitals, community clinics, and government health programs to improve bone health across the population. The company generates revenue by direct sales of their medical equipment and related services to healthcare institutions. The venture funding raised in April 2026 will help Innoray accelerate the domestic substitution of photon energy spectrum bone densitometers, promote the registration and mass production of five bone metabolism parameters, build a standardized bone metabolism diagnosis and treatment center, fully empower primary and private hospitals, explore new tracks in consumer healthcare, and jointly reshape the new ecosystem of orthopedic diagnosis and treatment.